RYR1 / RYR Antibody (C-Terminus)
Primary AntibodyLSBio Guarantee
| Antibody: | Rabbit Polyclonal |
| Applications: | Enzyme-Linked Immunosorbent Assay, Immunohistochemistry (general), Western Blot |
| Reactivity: | Human |
| Format: | Lyophilized |
$449.00each
Catalog Number: LS-C153542-50
Catalog Number: LS-C153542
For bulk orders or custom formulations:
Request a QuoteOverview
- Description
- RYR antibody LS-C153542 is an unconjugated rabbit polyclonal antibody to human RYR (RYR1) (C-Terminus). Validated for ELISA, IHC and WB. Cited in 1 publication.
- Application
- ELISA, IHC, WB
- Reactivity
- Hu
- Intended Use
- Research Use Only
- Guarantees
- This antibody carries the LSBio 100% Guarantee. ✓
- Category
- Antibodies > Primary Antibodies > Polyclonal Antibodies
- Alternative Names
- CCO | Central core disease of muscle | MHS | RYDR | Ryanodine receptor type 1 | RYR-1 | RYR1 | SKRR | Type 1 ryanodine receptor | Ryanodine receptor 1 | Ryanodine receptor type1 | MHS1 | RyR | Type 1-like ryanodine receptor
- UniProt Number
- P21817
- NCBI GenBank
- NM_000540 | NP_000531.2
- SwissProt
- P21817
Target
- Target
- Human RYR1 / RYR
- Antigen Species
- Human
- Epitope
- Reacts with human 565 kD protein. Cross reacts with proteins from rat, mouse and other species.
- Gene Name
- RYR1
Antibody
- Host Species
- Rabbit
- Clonality
- Polyclonal
Immunogen
- Immunogen
- Synthetic peptide derived from Cter domain of human RYR-1 protein.
- Immunogen Type
- Synthetic Peptide (Linear)
Format
- Conjugate/Label
- Unconjugated
- Format
- Lyophilized
- Formulation
- 100 mM Tris-glycine, 2% sucrose
- Preservative
- No
- Purification Method
- Protein A Affinity
Storage & Handling
- Storage Conditions
- Lyophilized powder stable for a minimum of 2 years at -20°C. Store reconstituted antibodies at 4°C. For extended periods store in aliquots at -20°C.
- Recommended Storage Buffer
- 100 mM Tris-glycine
Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle. Farini A, Sitzia C, Cassinelli L, Colleoni F, Parolini D, Giovanella U, Maciotta S, Colombo A, Meregalli M, Torrente Y. Development (Cambridge, England). 2016 February;143:658-69. PubMed: 26884398